Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$41.06
+1.2%
$45.75
$25.20
$48.52
$14.87B1.772.10 million shs2.77 million shs
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
C$10.64
+0.1%
C$10.18
C$7.79
C$10.94
C$1.93B1.2555,544 shs580,767 shs
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
C$7.99
C$7.99
C$1.55
C$8.50
C$1.63BN/A1.13 million shs337,797 shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$27.48
+4.5%
$35.81
$24.60
$63.57
$3.27B1.941.97 million shs2.39 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
+1.18%-10.95%-12.40%+0.27%+38.02%
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
+0.09%-1.48%+3.50%+23.86%+4.01%
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
0.00%0.00%0.00%0.00%0.00%
10x Genomics, Inc. stock logo
TXG
10x Genomics
+4.53%-0.40%-24.40%-36.97%-49.11%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
4.3569 of 5 stars
2.31.01.72.63.14.22.5
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
4.1713 of 5 stars
3.50.01.70.03.42.52.5
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
0.6184 of 5 stars
2.60.00.00.00.60.81.3
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.4302 of 5 stars
4.31.00.04.81.63.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
2.50
Moderate Buy$44.257.77% Upside
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
3.00
BuyC$13.7829.52% Upside
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
3.13
BuyC$9.9824.84% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.58
Moderate Buy$48.5076.49% Upside

Current Analyst Ratings

Latest TXG, KNT, CG, and DPM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$56.00 ➝ $47.00
5/2/2024
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$49.00 ➝ $45.00
5/2/2024
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$54.00 ➝ $48.00
5/2/2024
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$50.00 ➝ $48.00
5/2/2024
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$74.00 ➝ $68.00
5/2/2024
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetC$13.25 ➝ C$14.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$52.00 ➝ $30.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$30.00 ➝ $26.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$45.00 ➝ $36.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$63.00 ➝ $53.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$57.00 ➝ $32.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$2.96B5.02$4.53 per share9.07$15.85 per share2.59
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
C$520.09M3.71C$3.82 per share2.79C$6.18 per share1.72
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
C$144.51M11.29C$0.19 per share42.50C$0.75 per share10.65
10x Genomics, Inc. stock logo
TXG
10x Genomics
$618.73M5.29N/AN/A$6.03 per share4.56

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
-$608.40M-$1.79N/A9.170.86-23.04%23.92%7.00%8/7/2024 (Estimated)
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
C$181.98MC$1.338.000.0437.10%17.22%9.53%5/7/2024 (Confirmed)
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
N/AC$0.2532.48N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$255.10M-$2.23N/AN/AN/A-42.20%-30.85%-24.17%8/1/2024 (Estimated)

Latest TXG, KNT, CG, and DPM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
C$0.27N/A-C$0.27N/AN/AN/A
5/1/2024Q1 2024
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$0.92$1.01+$0.09$1.84$986.10 million$1.02 billion  
4/30/2024Q1 2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.50-$0.50N/A-$0.50$142.24 million$141.01 million    
2/15/2024Q4 2023
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.36-$0.41-$0.05-$0.41$182.73 million$183.98 million    
2/14/2024Q4 2023
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
C$0.48C$0.38-C$0.10C$0.32N/AC$189.66 million
2/7/202412/31/2023
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$0.78$0.86+$0.08$3.64$860.68 million$896.40 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$1.403.41%+11.20%N/A 2 Years
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
C$0.222.07%N/A16.54%N/A
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Latest TXG, KNT, CG, and DPM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
Quarterly$0.353.45%5/13/20245/14/20245/21/2024
2/14/2024
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
QuarterlyC$0.052.57%3/27/20243/31/20244/15/2024
2/6/2024
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
quarterly$0.353.1%2/22/20242/23/20243/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
1.53
2.53
2.27
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
0.28
6.70
6.61
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
4.93
3.25
2.43
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
5.22
4.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
55.88%
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
63.89%
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
27.20%
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
0.11%
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
10.65%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
2,200362.11 million263.62 millionOptionable
Dundee Precious Metals Inc. stock logo
DPM
Dundee Precious Metals
147,000181.43 millionN/ANot Optionable
K92 Mining Inc. (KNT.V) stock logo
KNT
K92 Mining Inc. (KNT.V)
N/A204.20 millionN/ANot Optionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,259119.17 million106.48 millionOptionable

TXG, KNT, CG, and DPM Headlines

SourceHeadline
Research Analysts Issue Forecasts for 10x Genomics, Inc.s Q2 2024 Earnings (NASDAQ:TXG)Research Analysts Issue Forecasts for 10x Genomics, Inc.'s Q2 2024 Earnings (NASDAQ:TXG)
americanbankingnews.com - May 4 at 1:42 AM
Q2 2024 Earnings Estimate for 10x Genomics, Inc. Issued By William Blair (NASDAQ:TXG)Q2 2024 Earnings Estimate for 10x Genomics, Inc. Issued By William Blair (NASDAQ:TXG)
marketbeat.com - May 3 at 7:28 AM
10x Genomics (NASDAQ:TXG) PT Lowered to $36.0010x Genomics (NASDAQ:TXG) PT Lowered to $36.00
americanbankingnews.com - May 3 at 5:14 AM
10x Genomics (NASDAQ:TXG) Stock Rating Lowered by TD Cowen10x Genomics (NASDAQ:TXG) Stock Rating Lowered by TD Cowen
americanbankingnews.com - May 3 at 5:14 AM
The Goldman Sachs Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $26.00The Goldman Sachs Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $26.00
americanbankingnews.com - May 3 at 5:14 AM
Stifel Nicolaus Lowers 10x Genomics (NASDAQ:TXG) Price Target to $53.00Stifel Nicolaus Lowers 10x Genomics (NASDAQ:TXG) Price Target to $53.00
americanbankingnews.com - May 3 at 5:14 AM
10x Genomics (NASDAQ:TXG) PT Lowered to $30.0010x Genomics (NASDAQ:TXG) PT Lowered to $30.00
americanbankingnews.com - May 3 at 5:14 AM
10x Genomics to Present at the BofA Securities 2024 Healthcare Conference10x Genomics to Present at the BofA Securities 2024 Healthcare Conference
prnewswire.com - May 2 at 4:05 PM
TD Cowen Downgrades 10x Genomics (TXG)TD Cowen Downgrades 10x Genomics (TXG)
msn.com - May 2 at 7:37 AM
10x Genomics First Quarter 2024 Earnings: In Line With Expectations10x Genomics First Quarter 2024 Earnings: In Line With Expectations
finance.yahoo.com - May 2 at 7:37 AM
10x Genomics, Inc: 10x Genomics Reports First Quarter 2024 Financial Results10x Genomics, Inc: 10x Genomics Reports First Quarter 2024 Financial Results
finanznachrichten.de - May 2 at 2:37 AM
10x Genomics (NASDAQ:TXG) Sets New 12-Month Low After Analyst Downgrade10x Genomics (NASDAQ:TXG) Sets New 12-Month Low After Analyst Downgrade
americanbankingnews.com - May 2 at 1:18 AM
10x Genomics (NASDAQ:TXG) Given New $30.00 Price Target at UBS Group10x Genomics (NASDAQ:TXG) Given New $30.00 Price Target at UBS Group
marketbeat.com - May 1 at 2:32 PM
10x Genomics (NASDAQ:TXG) Hits New 12-Month Low After Analyst Downgrade10x Genomics (NASDAQ:TXG) Hits New 12-Month Low After Analyst Downgrade
marketbeat.com - May 1 at 11:34 AM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)Analysts’ Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)
markets.businessinsider.com - May 1 at 8:41 AM
10x Genomics (NASDAQ:TXG) Downgraded by TD Cowen10x Genomics (NASDAQ:TXG) Downgraded by TD Cowen
marketbeat.com - May 1 at 8:32 AM
Canaccord Genuity Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $50.00Canaccord Genuity Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $50.00
americanbankingnews.com - May 1 at 5:32 AM
10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...
finance.yahoo.com - May 1 at 3:41 AM
Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)
businesswire.com - May 1 at 1:01 AM
10x Genomics: Q1 Earnings Snapshot10x Genomics: Q1 Earnings Snapshot
sfgate.com - April 30 at 10:41 PM
TXG Stock Earnings: 10x Genomics Meets EPS, Misses Revenue for Q1 2024TXG Stock Earnings: 10x Genomics Meets EPS, Misses Revenue for Q1 2024
markets.businessinsider.com - April 30 at 10:41 PM
10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com - April 30 at 7:31 PM
10x Genomics Inc (TXG) Q1 2024 Earnings: Misses Analyst Expectations Amidst New Product Launches10x Genomics Inc (TXG) Q1 2024 Earnings: Misses Analyst Expectations Amidst New Product Launches
finance.yahoo.com - April 30 at 6:17 PM
10x Genomics (NASDAQ:TXG) Releases  Earnings Results, Misses Estimates By $0.04 EPS10x Genomics (NASDAQ:TXG) Releases Earnings Results, Misses Estimates By $0.04 EPS
marketbeat.com - April 30 at 5:08 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

The Carlyle Group logo

The Carlyle Group

NASDAQ:CG
The Carlyle Group Inc. is an investment firm specializing in direct and fund of fund investments. Within direct investments, it specializes in management-led/ Leveraged buyouts, privatizations, divestitures, strategic minority equity investments, structured credit, global distressed and corporate opportunities, small and middle market, equity private placements, consolidations and buildups, senior debt, mezzanine and leveraged finance, and venture and growth capital financings, seed/startup, early venture, emerging growth, turnaround, mid venture, late venture, PIPES. The firm invests across four segments which include Corporate Private Equity, Real Assets, Global Market Strategies, and Solutions. The firm typically invests in industrial, agribusiness, ecological sector, fintech, airports, parking, Plastics, Rubber, diversified natural resources, minerals, farming, aerospace, defense, automotive, consumer, retail, industrial, infrastructure, energy, power, healthcare, software, software enabled services, semiconductors, communications infrastructure, financial technology, utilities, gaming, systems and related supply chain, electronic systems, systems, oil and gas, processing facilities, power generation assets, technology, systems, real estate, financial services, transportation, business services, telecommunications, media, and logistics sectors. Within the industrial sector, the firm invests in manufacturing, building products, packaging, chemicals, metals and mining, forestry and paper products, and industrial consumables and services. In consumer and retail sectors, it invests in food and beverage, retail, restaurants, consumer products, domestic consumption, consumer services, personal care products, direct marketing, and education. Within aerospace, defense, business services, and government services sectors, it seeks to invest in defense electronics, manufacturing and services, government contracting and services, information technology, distribution companies. In telecommunication and media sectors, it invests in cable TV, directories, publishing, entertainment and content delivery services, wireless infrastructure/services, fixed line networks, satellite services, broadband and Internet, and infrastructure. Within real estate, the firm invests in office, hotel, industrial, retail, for sale residential, student housing, hospitality, multifamily residential, homebuilding and building products, and senior living sectors. The firm seeks to make investments in growing business including those with overleveraged balance sheets. The firm seeks to hold its investments for four to six years. In the healthcare sector, it invests in healthcare services, outsourcing services, companies running clinical trials for pharmaceutical companies, managed care, pharmaceuticals, pharmaceutical related services, healthcare IT, medical, products, and devices. It seeks to invest in companies based in Sub-Saharan focusing on Ghana, Kenya, Mozambique, Botswana, Nigeria, Uganda, West Africa, North Africa and South Africa focusing on Tanzania and Zambia; Asia focusing on Pakistan, India, South East Asia, Indonesia, Philippines, Vietnam, Korea, and Japan; Australia; New Zealand; Europe focusing on France, Italy, Denmark, United Kingdom, Germany, Austria, Belgium, Finland, Iceland, Ireland, Netherlands, Norway, Portugal, Spain, Benelux , Sweden, Switzerland, Hungary, Poland, and Russia; Middle East focusing on Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey, and UAE; North America focusing on United States which further invest in Southeastern United States, Texas, Boston, San Francisco Bay Area and Pacific Northwest; Asia Pacific; Soviet Union, Central-Eastern Europe, and Israel; Nordic region; and South America focusing on Mexico, Argentina, Brazil, Chile, and Peru. The firm seeks to invest in food, financial, and healthcare industries in Western China. In the real estate sector, the firm seeks to invest in various locations across Europe focusing on France and Central Europe, United States, Asia focusing on China, and Latin America. It typically invests between $1 million and $50 million for venture investments and between $50 million and $2 billion for buyouts in companies with enterprise value of between $31.57 million and $1000 million and sales value of $10 million and $500 million. It seeks to invest in companies with market capitalization greater than $50 million and EBITDA between $5 million to $25 million. It prefers to take a majority or a minority stake. While investing in Japan, it does not invest in companies with more than 1,000 employees and prefers companies' worth between $100 million and $150 million. The firm originates, structures, and acts as lead equity investor in the transactions. The Carlyle Group Inc. was founded in 1987 and is based in Washington, District of Columbia with additional offices in 21 countries across 5 continents (North America, South America, Asia, Australia and Europe).
Dundee Precious Metals logo

Dundee Precious Metals

TSE:DPM
Dundee Precious Metals Inc., a gold mining company, engages in the acquisition, exploration, development, mining, and processing of precious metals. The company primarily explores for gold, copper, and silver deposits. It holds a portfolio of projects located in Bulgaria, Namibia, Serbia, and Ecuador. The company is based in Toronto, Canada.
K92 Mining Inc. (KNT.V) logo

K92 Mining Inc. (KNT.V)

CVE:KNT
K92 Mining Inc. engages in the mining, exploration, and development of mineral deposits in Papua New Guinea. The company produces gold, copper, and silver. Its principal property is the Kainantu property that covers an area of 725 square kilometers located in the Eastern Highlands province. The company is headquartered in Vancouver, Canada.
10x Genomics logo

10x Genomics

NASDAQ:TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.